CASI Pharmaceuticals, Inc. · OTC:CASIF
CASI Pharmaceuticals — Shareholder Meeting (June 2018)
21 slides from CASI Pharmaceuticals's shareholder meeting presentation, Jun 11, 2018
Slide 1: Corporate Presentation 2018 Annual Stockholder's Meeting
Corporate(Presentation 2018(Annual(Stockholder’s(Meeting June(11,(2018 Rockville,(Maryland
Slide 2: Forward-Looking Statements
Forward'Looking-Statements This presentation contains forward'looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward' looking statemen
Slide 3: Investment Highlights (1)
Investment-Highlights-(1) • Management:(Experienced-team-with-accomplished-track-record-in-North-America-and- China • Diversified product portfolio: ― In#licensed*FDA*approved*products*for*greater*China*from*Spectrum* Pharmaceuticals ― EVOMELA®-(CE'Melphalan),-granted-priority-review-by-China-Food-a
Slide 4: Investment Highlights (2)
Investment-Highlights-(2) • Compelling(business(model:(Capitalizing-on-critical-U.S./China-synergies-&-competitive- advantages-for-efficient/cost'effective-drug-development-and-commercialization ― Rockville,-MD ― Corporate-office,-senior-management,-finance,-accounting,-compliance,- regulatory-opera
Slide 5: Business Premise
Business-Premise • 1.4-billion-people-in-China-+-325-million-people-in-the-U.S.-demand-high-quality-and- affordable-medicines • Recent-CFDA-reforms-allow-for-expedited-approvals-of-FDA-ANDAs-and-innovative- products • CASI-is-in-a-unique-position-to-leverage-the-CFDA-reforms-by-introducing-FDA'appro
Slide 6: Financial Highlights
Financial-Highlights 12(Months(Ended(December(31, Three(Months(Ended(March(31 2017 2016 2018 2017 Total(revenues $ ' $ ' $ ' $ ' Research(&(development 7,595,182 4,645,560 1,697,232 1,049,287 General(&(administrative 3,156,138 4,775,050 1,303,122 644,163 Net(loss (10,770,202) (9,453,488) (3,590,910)
Slide 7: Bi-Cultural Board & Management Team
Bi'Cultural-Board-&-Management-Team BOARD(OF(DIRECTORS Dr.(WeiGWu(He, Executive(Chairman( IDG'ACCEL-China-Fund-Venture-Partner;-Managing-Director-of- ETP-Global-Fund,-L.P.;-Chairman-&-CEO,-OriGene Technologies,-Inc. Dr.(Quan Zhou Founder,-Managing-Director-and-General-Partner-at-IDG- Capital- Partne
Slide 8: Diversified Product Portfolio
Diversified-Product-Portfolio- Through*Acquisitions,*In#licensing*and*Internally*Developed*Innovative,* Targeted*Oncology*Therapeutics*and*High*Quality*ANDAs Greater(China(Rights Acquired)From)SPPI US(FDA(ANDAs ENMDG2076,(Global(Rights Acquired)From)Sandoz •25-FDA-Approved-ANDAs Innovative-Drug-Cand
Slide 9: Licensed Products
Licensed-Products • CASI-entered-into-licensing-agreement-with-Spectrum-Pharmaceuticals-for-China-development- &-commercialization-of-three-hematological-oncology-products • Exclusive(rights(to(three(commercial(products: ― EVOMELA ® Conditioning)treatment)prior)to)autologous)stem)cell)transplant)for
Slide 10: Evomela: China Market Potential
Evomela®:-China-Market-Potential-- • Status:-CFDA*priority*review;*Expert*Clinical*Advisory*Committee*meeting*took*place*on* April*26,*2018 • Import-drug-application-for-EVOMELA-granted-priority(review(by-CFDA,-underpinning-high- unmet-medical-need-and-advantages-to-currently-available-therapeutics
Slide 11: Marqibo: China Market Potential
Marqibo®:-China-Market-Potential-- • Status:(CFDA*review*in*progress • Proprietary-liposomal-formulation-of-vincristine-which-improves-pharmacokinetics- and-pharmacodynamics-of-vincristine* – Higher)maximum)tolerated)dose,)superior)antitumor)activity)and)higher) amounts)of)active)drug)delivered)to)t
Slide 12: Zevalin: China Market Potential
Zevalin®:-China-Market-Potential-- • Status:*CFDA*review*in*progress • Anti'CD20-antibody-coupled-to-Yttrium'90 ̶ 83%-ORR,-39%-CR-in-relapsed-or-refractory,-low'grade-or-follicular-B'cell- NHL (FNHL) • Annual-incidence-of-NHL-in-China-estimated-at-~84k-new-cases-with-mortality-of- ~50k-cases-in-2015
Slide 13: 29 ANDA Products & Pipeline
29-ANDA-Products-&-Pipeline 25(FDA(Approved,(4(Pending(FDA(Approval(ANDAs Diverse.Portfolio.Across.Attractive. Therapeutic.Area 12% 35% 19% 15% 8% 11% Hypertension/PVD Metabolic.Disorders CNS AntiFinfectious AntiFinflammatory/pain Others Slide-13
Slide 14: Historical Opportunity for FDA-Approved ANDAs in China
Historical-Opportunity-for-FDA'Approved-ANDAs-in-China Rapidly)Establishing)Leading)Position)in)China’s)>$100B)Small)Molecule)Drug)Market) Rapid(Entry( Technology(Barriers,( Opportunity(for( Industry(Consolidations CFDA’s(BioG CFDA’s(BE( Waiver(on( FDA(ANDA( Equivalence( Products ReGEvaluation( Chin
Slide 15: China Market for 5 Key ANDA Products
China-Market-for-5-Key-ANDA-Products- Key(Products(Based(on(2016((Estimated)(Generic(Sales(in(China Product Indication 2016E(Sales((in(US$) 1 Entecavir(tablet Chronic(HBV(Infection 1,490,000,000 2 Bisoprolol-Fumarate- Hypertension 205,000,000 tablet 3 Desvenlafaxine SR-tablet Depression 170,000,000
Slide 16: U.S. Market for 8 Key ANDA Products
U.S.-Market-for-8-Key-ANDA-Products Key(ANDAs(2016(U.S.(Sales* Product(Name Indications Sandoz(U.S.(Sales( Overall(U..S(Generic( 2016((IMS(data) Sales(2016((IMS(data) 1 Midodrine Hypotension 19,800,000 56,900,000 2 Triamterene-/-HCTZ-cap- Hypertension,-diuretic 4,600,000 54,000,000 3 Lisinopril-tab
Slide 17: ENMD-2076 Update (1)
ENMD'2076-Update-(1) • Clear)Cell)Ovarian)Carcinoma)(CCOC) – Phase-2-data-presented-at-the-2017-Annual-Meeting-of-the-American-Society-of-Clinical- Oncology.-1/38-patients-responded,-several-patients-with-protracted-stable-disease – Biomarker)studies)ongoing • Soft)Tissue)Sarcoma)(STS). – Phase-2-da
Slide 18: ENMD-2076 Update (2)
ENMD'2076-Update-(2) • Fibrolamellar)Carcinoma)(FLC). The-accrual-to-this-ongoing-Phase-2-study-is-complete- and-is-in-data-clean-up-and-analysis-phase.-It-is-anticipated-that-the-data-from-this- study-will-be-submitted-to-a-medical-conference-for-presentation-in-2018.--- • Phase-1/2-study-in-patien
Slide 19: Summary
Summary • On track with a Diversified product portfolio: ― In#licensed*FDA*approved*products*for*greater*China*from*Spectrum* Pharmaceuticals ― EVOMELA®-(CE'Melphalan),-granted-priority-review-by-China-Food-and-Drug- Administration-(CFDA)- ― MARQIBO®-(vinCRIStine-sulfate-LIPOSOME),-CFDA-review-in-pr
Slide 20: Thank you
Thank you harmaceuticals
Slide 21: NASDAQ: CASI www.casipharmaceuticals.com
NASDAQ:-CASI www.casipharmaceuticals.com
CASI Pharmaceuticals — Shareholder Meeting (June 2018) on 6ix